{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:05:35Z","timestamp":1787994335305,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["95-04-128-30299"],"award-info":[{"award-number":["95-04-128-30299"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00705-020-04728-x","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T01:02:36Z","timestamp":1594170156000},"page":"2193-2203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study"],"prefix":"10.1007","volume":"165","author":[{"given":"Fahimeh","family":"Safarnezhad Tameshkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hadi","family":"Karbalaie Niya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Motamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Ajdarkosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid","family":"Vafaeimanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoodreza","family":"Khoonsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood Reza","family":"Sohrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Aten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azita","family":"Azarkeivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh Sadat","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhayaneethie","family":"Perumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansooreh","family":"Maadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrooz","family":"Ghanbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-5982","authenticated-orcid":false,"given":"Hossein","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"4728_CR1","unstructured":"AASLD-IDSA (2019) HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. https:\/\/www.hcvguidelines.org\/full-report\/hcv-testing-and-linkage-care"},{"key":"4728_CR2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/AZMJ.AZMJ_22_18","volume":"16","author":"M Abd Alla","year":"2018","unstructured":"Abd Alla M, Gomaa A, Farrag GA, Shikhroho M, Mousa W, Mahmoud O (2018) Retrospective study of hepatitis c virus relapse after treatment with sofosbuvir and daclatasvir with or without ribavirin. Al-Azhar Assiut Med J 16:197\u2013204","journal-title":"Al-Azhar Assiut Med J"},{"key":"4728_CR3","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski J-P, Agarwal K, Buggisch P (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889\u20131898","journal-title":"N Engl J Med"},{"key":"4728_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.15171\/mejdd.2017.88","volume":"10","author":"S Ahmadi-Ghezeldasht","year":"2018","unstructured":"Ahmadi-Ghezeldasht S, Badiei Z, Sima HR, Hedayati-Moghaddam MR, Habibi M, Khamooshi M, Azimi A (2018) Distribution of hepatitis C virus genotypes in patients with major \u03b2-thalassemia in Mashhad, Northeast Iran. Middle East J Dig Dis 10:35","journal-title":"Middle East J Dig Dis"},{"key":"4728_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3324\/haematol.13500","volume":"93","author":"E Angelucci","year":"2008","unstructured":"Angelucci E, Pilo F (2008) Treatment of hepatitis C in patients with thalassemia. Haematologica 93:1121\u20131123. https:\/\/doi.org\/10.3324\/haematol.13500","journal-title":"Haematologica"},{"key":"4728_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14218\/JCTH.2017.00067","volume":"6","author":"P Axley","year":"2018","unstructured":"Axley P, Ahmed Z, Ravi S, Singal AK (2018) Hepatitis C virus and hepatocellular carcinoma: a narrative review. J Clin Transl Hepatol 6:79","journal-title":"J Clin Transl Hepatol"},{"key":"4728_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/v11020148","volume":"11","author":"S Bagaglio","year":"2019","unstructured":"Bagaglio S, Messina E, Hasson H, Galli A, Uberti-Foppa C, Morsica G (2019) Geographic distribution of HCV-GT3 subtypes and naturally occurring resistance associated substitutions. Viruses 11:148","journal-title":"Viruses"},{"key":"4728_CR8","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1128\/JVI.02294-12","volume":"87","author":"DJ Bartels","year":"2013","unstructured":"Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G (2013) Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 87:1544\u20131553","journal-title":"J Virol"},{"key":"4728_CR9","first-page":"1131","volume":"163","author":"M Behzadifar","year":"2018","unstructured":"Behzadifar M, Gorji HA, Bragazzi NL (2018) The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. Adv Virol 163:1131\u20131140","journal-title":"Adv Virol"},{"key":"4728_CR10","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3390\/cells8070666","volume":"8","author":"MC Bellocchi","year":"2019","unstructured":"Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F (2019) NS5A gene analysis by next generation sequencing in HCV nosocomial transmission clusters of HCV genotype 1b infected patients. Cells 8:666","journal-title":"Cells"},{"key":"4728_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/14656566.2016.1182156","volume":"17","author":"L Ben\u00edtez-Guti\u00e9rrez","year":"2016","unstructured":"Ben\u00edtez-Guti\u00e9rrez L, Barreiro P, Labarga P, de Mendoza C, Fernandez-Montero JV, Arias A, Pe\u00f1a JM, Soriano V (2016) Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother 17:1215\u20131223","journal-title":"Expert Opin Pharmacother"},{"key":"4728_CR12","doi-asserted-by":"publisher","first-page":"104694","DOI":"10.1016\/j.antiviral.2019.104694","volume":"174","author":"Q Chen","year":"2020","unstructured":"Chen Q, Perales C, Soria ME, Garc\u00eda-Cehic D, Gregori J, Rodr\u00edguez-Fr\u00edas F, Buti M, Crespo J, Calleja JL, Tabernero D (2020) Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antivir Res 174:104694","journal-title":"Antivir Res"},{"key":"4728_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"Q-L Choo","year":"1989","unstructured":"Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359\u2013362","journal-title":"Science"},{"key":"4728_CR14","doi-asserted-by":"publisher","first-page":"175628481875948","DOI":"10.1177\/1756284818759483","volume":"11","author":"E Crouchet","year":"2018","unstructured":"Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF (2018) Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Ther Adv Gastroenterol 11:1756284818759483","journal-title":"Ther Adv Gastroenterol"},{"key":"4728_CR15","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1128\/AAC.02386-13","volume":"58","author":"V Di Maio","year":"2014","unstructured":"Di Maio V, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S, Perno C, Ceccherini-Silberstein F (2014) Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother 58:2781\u20132797","journal-title":"Antimicrob Agents Chemother"},{"key":"4728_CR16","doi-asserted-by":"publisher","first-page":"e0134395","DOI":"10.1371\/journal.pone.0134395","volume":"10","author":"J Dietz","year":"2015","unstructured":"Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C (2015) Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients. PLoS ONE 10:e0134395","journal-title":"PLoS ONE"},{"key":"4728_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IJGM.S119301","volume":"10","author":"A Elgharably","year":"2017","unstructured":"Elgharably A, Gomaa AI, Crossey MM, Norsworthy PJ, Waked I, Taylor-Robinson SD (2017) Hepatitis C in Egypt\u2014past, present, and future. Int J Gen Med 10:1","journal-title":"Int J Gen Med"},{"key":"4728_CR18","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/17425255.2016.1209484","volume":"12","author":"I Esposito","year":"2016","unstructured":"Esposito I, Trinks J, Soriano V (2016) Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol 12:1197\u20131209","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4728_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1515\/jtim-2017-0007","volume":"5","author":"A Geddawy","year":"2017","unstructured":"Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA (2017) Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. J Transl Intern Med 5:8\u201317","journal-title":"J Transl Intern Med"},{"key":"4728_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.antiviral.2015.01.004","volume":"119","author":"CS Graham","year":"2015","unstructured":"Graham CS, Swan T (2015) A path to eradication of hepatitis C in low-and middle-income countries. Antivir Res 119:89\u201396","journal-title":"Antivir Res"},{"key":"4728_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/03630269.2019.1628774","volume":"43","author":"M Hadipour Dehshal","year":"2019","unstructured":"Hadipour Dehshal M, Tabrizi Namini M, Hantoushzadeh R, Yousefi Darestani S (2019) \u03b2-Thalassemia in Iran: things everyone needs to know about this disease. Hemoglobin 43:166\u2013173","journal-title":"Hemoglobin"},{"key":"4728_CR22","first-page":"10","volume":"17","author":"LL Haiyan Zeng","year":"2020","unstructured":"Haiyan Zeng LL, Hou Z, Zhang Y, Tang Z, Liu S (2020) Direct-acting antiviral in the treatment of chronic hepatitis C: bonuses and challenges. Int J Med Sci 17:10","journal-title":"Int J Med Sci"},{"key":"4728_CR23","doi-asserted-by":"publisher","first-page":"vex041","DOI":"10.1093\/ve\/vex041","volume":"4","author":"BR Jones","year":"2018","unstructured":"Jones BR, Howe AY, Harrigan PR, Joy JB (2018) The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus. Virus Evol 4:vex041","journal-title":"Virus Evol"},{"key":"4728_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/jmv.25279","volume":"91","author":"R Kahyesh-Esfandiary","year":"2019","unstructured":"Kahyesh-Esfandiary R, Sadigh ZA, Esghaei M, Bastani MN, Donyavi T, Najafi A, Fakhim A, Bokharaei-Salim F (2019) Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta-thalassemia major: Occult HCV infection. J Med Virol 91:107\u2013114","journal-title":"J Med Virol"},{"key":"4728_CR25","doi-asserted-by":"publisher","first-page":"e22915","DOI":"10.5812\/hepatmon.22915","volume":"14","author":"M Khodabandehloo","year":"2014","unstructured":"Khodabandehloo M, Roshani D (2014) Prevalence of hepatitis C virus genotypes in Iranian patients: a systematic review and meta-analysis. Hepat Mon 14:e22915","journal-title":"Hepat Mon"},{"key":"4728_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-pharmtox-011112-140254","volume":"53","author":"JJ Kiser","year":"2013","unstructured":"Kiser JJ, Flexner C (2013) Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol 53:427\u2013449","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4728_CR27","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M (2014) Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370:1879\u20131888","journal-title":"N Engl J Med"},{"key":"4728_CR28","doi-asserted-by":"publisher","first-page":"S498","DOI":"10.1016\/S0168-8278(14)61390-8","volume":"60","author":"P Krishnan","year":"2014","unstructured":"Krishnan P, Tripathi R, Irvin M, Beyer J, Reisch T, Schnell G, Xie W, Zhou X, Larsen L, Kofron J (2014) P1230 lack of impact of baseline resistance-associated variants (RAVS) on treatment outcome in the aviator study with ABT-450\/R, ABT-333 AND ABT-267,+\/\u2013Ribavirin. J Hepatol 60:S498","journal-title":"J Hepatol"},{"key":"4728_CR29","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1128\/AAC.00998-15","volume":"59","author":"P Krishnan","year":"2015","unstructured":"Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T (2015) Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother 59:5445\u20135454","journal-title":"Antimicrob Agents Chemother"},{"key":"4728_CR30","doi-asserted-by":"crossref","unstructured":"Li Z, Liu Y, Zhang Y, Shao X, Luo Q, Guo X, Lin G, Cai Q, Zhao Z, Chong Y (2017) Naturally occurring resistance-associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 6a-infected patients. BioMed Res Int 2017","DOI":"10.1155\/2017\/9849823"},{"key":"4728_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1186\/s12879-017-2817-7","volume":"17","author":"F Malta","year":"2017","unstructured":"Malta F, Gaspareto KV, Lisboa-Neto G, Carrilho FJ, Mendes-Correa MC, Pinho JRR (2017) Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. BMC Infect Dis 17:716","journal-title":"BMC Infect Dis"},{"issue":"1","key":"4728_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/17474086.2020.1686354","volume":"13","author":"I Motta","year":"2020","unstructured":"Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD (2020) Management of age-associated medical complications in patients with \u03b2-thalassemia. Expert Rev Hematol 13(1):85\u201394","journal-title":"Expert Rev Hematol"},{"key":"4728_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jceh.2017.08.002","volume":"7","author":"A Nagral","year":"2017","unstructured":"Nagral A, Sawant S, Nagral N, Parikh P, Malde P, Merchant R (2017) Generic direct acting antivirals in treatment of chronic hepatitis C infection in patients of thalassemia major. J Clin Exp Hepatol 7:172\u2013178","journal-title":"J Clin Exp Hepatol"},{"key":"4728_CR34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.micpath.2017.01.060","volume":"105","author":"MHK Niya","year":"2017","unstructured":"Niya MHK, Salman-Tabar S, Bokharaei-Salim F, Behmanesh M, Keyvani H (2017) Prevalence of resistant associated variants (RAVs) in the na\u00efve HCV patient candidate for direct acting antiviral (DAA) therapy. Microb Pathog 105:166\u2013170","journal-title":"Microb Pathog"},{"key":"4728_CR35","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1128\/AAC.02776-15","volume":"60","author":"J\u00c1 Pati\u00f1o-Galindo","year":"2016","unstructured":"Pati\u00f1o-Galindo J\u00c1, Salvatierra K, Gonz\u00e1lez-Candelas F, L\u00f3pez-Labrador FX (2016) Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. Antimicrob Agents Chemother 60:2402\u20132416","journal-title":"Antimicrob Agents Chemother"},{"key":"4728_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"J-M Pawlotsky","year":"2016","unstructured":"Pawlotsky J-M (2016) Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151:70\u201386","journal-title":"Gastroenterology"},{"key":"4728_CR37","doi-asserted-by":"crossref","unstructured":"Pawlotsky J-M (2019) Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures. In: Seminars in liver disease. Thieme Medical Publishers","DOI":"10.1055\/s-0039-1687823"},{"key":"4728_CR38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/voxs.12477","volume":"14","author":"AA Pourfathollah","year":"2019","unstructured":"Pourfathollah AA, Hadipour Dehshal M (2019) Thalassaemia in Iran: Thalassaemia prevention and blood adequacy for thalassaemia treatment. ISBT Sci Ser 14:114\u2013118","journal-title":"ISBT Sci Ser"},{"key":"4728_CR39","doi-asserted-by":"publisher","first-page":"652","DOI":"10.5114\/aoms.2017.66022","volume":"13","author":"D Salemovic","year":"2017","unstructured":"Salemovic D, Pesic-Pavlovic I, Jevtovic D, Bojovic K, Ranin J, Brmbolic B, Stanojevic M (2017) Intravenous drug use\u2013an independent predictor for HCV genotypes 3 and 4 infection among HIV\/HCV co-infected patients. Arch Med Sci AMS 13:652","journal-title":"Arch Med Sci AMS"},{"key":"4728_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Zeuzem S (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447\u2013462","journal-title":"Gastroenterology"},{"key":"4728_CR41","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1089\/mdr.2018.0358","volume":"25","author":"H Sharafi","year":"2019","unstructured":"Sharafi H, Ghalamkari S, Hassanshahi A, Alavian SM (2019) Pooled prevalence of NS5A resistance-associated substitutions in chronic HCV genotype 3 infection: a study based on deposited sequences in GenBank. Microb Drug Resist 25:1072\u20131079","journal-title":"Microb Drug Resist"},{"key":"4728_CR42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bbrc.2018.04.005","volume":"500","author":"Y Teraoka","year":"2018","unstructured":"Teraoka Y, Uchida T, Imamura M, Osawa M, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D (2018) Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. Biochem Biophys Res Commun 500:152\u2013157","journal-title":"Biochem Biophys Res Commun"},{"key":"4728_CR43","unstructured":"World-Health-Orgnization (2019) Hepatitis C, key facts. https:\/\/www.hoint\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"key":"4728_CR44","first-page":"103","volume":"25","author":"DL Wyles","year":"2017","unstructured":"Wyles DL, Luetkemeyer AF (2017) Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens. Top Antivir Med 25:103","journal-title":"Top Antivir Med"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-020-04728-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-020-04728-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-020-04728-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T13:34:40Z","timestamp":1723210480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-020-04728-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["4728"],"URL":"https:\/\/doi.org\/10.1007\/s00705-020-04728-x","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"17 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors do not have any competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated and\/or analyzed in the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}